Celldom, Inc.
Durham, NC · Medtech · Private
Microfluidic platform combining image-based phenotyping with single-cell transcriptomics using DNA-barcoded trap arrays
- Grants
- $7.1M
- 8 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 9
- 1 granted · 8 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20162018202020222024
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · High-throughput screening of arrayed single cells for automated analysis of phenotypic heterogeneity | $224,907 | |
| Federal grant | Department of Health and Human Services · Phase II · High-throughput screening of arrayed single cells for automated analysis of phenotypic heterogeneity | $1,480,039 | |
| Federal grant | Department of Health and Human Services · Phase I · Platform for genotyping and phenotyping each cell in a high throughput assay | $298,559 | |
| Federal grant | Department of Health and Human Services · Phase II · High-throughput screening of arrayed single cells for automated analysis of phenotypic heterogeneity | $728,478 | |
| Federal grant | Department of Health and Human Services · Phase II · Platform for genotyping and phenotyping each cell in a high throughput assay | $1,663,928 | |
| Federal grant | Department of Health and Human Services · Phase II · Platform for genotyping and phenotyping each cell in a high throughput assay | $831,964 | |
| Federal grant | Department of Health and Human Services · Phase II · High throughput CAR-T potency assay based on functional and transcriptional measurements on single cell co-cultures | $938,647 | |
| Federal grant | Department of Health and Human Services · Phase II · High throughput CAR-T potency assay based on functional and transcriptional measurements on single cell co-cultures | $908,687 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2278 | Frontier Diagnostics, LLC | — | — |
| 2279 | GLYCODOTS, LLC | — | — |
| 2280 | GLOBAL BIOMEDICAL TECHNOLOGIES, LLC | — | $1.0M |
| 2281 | Celldom, Inc. | — | — |
| 2282 | EARLY ALZHEIMER'S DIAGNOSTICS LLC | — | — |
| 2283 | Articulate Biosciences, LLC | — | — |
| 2284 | CAMERAD TECHNOLOGIES, LLC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Device And Method For Cell-based Drug Screeninggranted
- Protein Linker System For Conjugation And Release Of Oligonucleotidesapplication
- Fluorescent Barcoding Of Microparticlesapplication
- Methods and Devices for Single Cell Barcodingapplication
- Methods and Devices for Single Cell Barcodingapplication
- Methods And Devices For Cell Transfection And Gene Expression Assaysapplication
- Methods And Devices For Single Cell Barcodingapplication
- Fluorescent Barcoding Of Microparticlesapplication
- Methods And Devices For Single Cell Barcodingapplication
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.